Literature DB >> 11673370

Identification of alpha(1)-antitrypsin variants in plasma with the use of proteomic technology.

K Mills1, P B Mills, P T Clayton, A W Johnson, D B Whitehouse, B G Winchester.   

Abstract

BACKGROUND: Proteomic technology permits the investigation of genetic metabolic diseases at the level of protein expression. Changes in the expression, polypeptide structure, and posttranslational modification of individual proteins can be detected in complex mixtures of proteins.
METHODS: We used high-resolution two-dimensional polyacrylamide gel electrophoresis to separate isoforms of plasma proteins and detect abnormalities of mass and/or charge. We confirmed the identity of the separated proteins by in-gel digestion with proteases and N-glycanases and then analyzed the released peptides and glycans by matrix-assisted laser-desorption ionization-time-of-flight mass spectrometry.
RESULTS: Complete characterization of the polypeptide sequences and glycosylation of alpha(1)-antitrypsin isoforms was achieved in plasma from controls and from patients with three different known alpha(1)-antitrypsin deficiencies and congenital disorder of glycosylation type Ia.
CONCLUSIONS: This study shows that proteomic techniques are a powerful and sensitive means of detecting changes in the amino acid sequence and abnormal posttranslational modifications of specific proteins in a complex biologic matrix.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673370

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

Review 1.  Current perspectives in cancer proteomics.

Authors:  Miriam V Dwek; Sarah L Rawlings
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

2.  Probing serpin conformational change using mass spectrometry and related methods.

Authors:  Yuko Tsutsui; Anindya Sarkar; Patrick L Wintrode
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

Review 3.  Mass spectrometric analysis of glycans in elucidating the pathogenesis of CDG type IIx .

Authors:  P B Mills; K Mills; N Mian; B G Winchester; P T Clayton
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 4.  Advances in analytical mass spectrometry to improve screening for inherited metabolic diseases.

Authors:  Wulf Röschinger; Bernhard Olgemöller; Ralph Fingerhut; Bernhard Liebl; Adelbert A Roscher
Journal:  Eur J Pediatr       Date:  2003-11-14       Impact factor: 3.183

5.  A missense mutation in the bovine SLC35A3 gene, encoding a UDP-N-acetylglucosamine transporter, causes complex vertebral malformation.

Authors:  Bo Thomsen; Per Horn; Frank Panitz; Emøke Bendixen; Anette H Petersen; Lars-Erik Holm; Vivi H Nielsen; Jørgen S Agerholm; Jens Arnbjerg; Christian Bendixen
Journal:  Genome Res       Date:  2005-12-12       Impact factor: 9.043

6.  Quantitative analysis of core fucosylation of serum proteins in liver diseases by LC-MS-MRM.

Authors:  Junfeng Ma; Miloslav Sanda; Renhuizi Wei; Lihua Zhang; Radoslav Goldman
Journal:  J Proteomics       Date:  2018-02-07       Impact factor: 4.044

7.  Effects of glycosylation on the stability and flexibility of a metastable protein: the human serpin α(1)-antitrypsin.

Authors:  Anindya Sarkar; Patrick L Wintrode
Journal:  Int J Mass Spectrom       Date:  2011-04       Impact factor: 1.986

8.  A novel glycosylphosphatidylinositol-anchored glycoside hydrolase from Ustilago esculenta functions in β-1,3-glucan degradation.

Authors:  Masahiro Nakajima; Tetsuro Yamashita; Machiko Takahashi; Yuki Nakano; Takumi Takeda
Journal:  Appl Environ Microbiol       Date:  2012-06-08       Impact factor: 4.792

9.  Alpha-1 Antitrypsin Therapy for Autoimmune Disorders.

Authors:  Sihong Song
Journal:  Chronic Obstr Pulm Dis       Date:  2018-10-05

10.  Targeted biomarker discovery by high throughput glycosylation profiling of human plasma alpha1-antitrypsin and immunoglobulin A.

Authors:  L Renee Ruhaak; Carolien A M Koeleman; Hae-Won Uh; Jord C Stam; Diana van Heemst; Andrea B Maier; Jeanine J Houwing-Duistermaat; Paul J Hensbergen; P Eline Slagboom; André M Deelder; Manfred Wuhrer
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.